Literature DB >> 22013273

Rate of administration of intravenous ondansetron.

Smita Prakash1, Meenu Aggarwal.   

Abstract

Entities:  

Year:  2011        PMID: 22013273      PMCID: PMC3190531          DOI: 10.4103/0019-5049.84827

Source DB:  PubMed          Journal:  Indian J Anaesth        ISSN: 0019-5049


× No keyword cloud information.
Sir, Ondansetron, a selective 5- HT3 receptor antagonist, is a popular drug for prevention and treatment of postoperative nausea and vomiting (PONV) because of its efficacy, safety and lack of drug interactions. Although rare, cardiovascular adverse effects such as sinus bradycardia, atrial fibrillation, prolongation of QTc interval and fatal ventricular tachycardia have been reported following administration of ondansetron.[1-4] A case of severe bradycardia with respiratory arrest and loss of consciousness has been described.[5] Most of the case reports regarding serious adverse effects, including that reported in Indian Journal of Anaesthesia by Sahu et al.,[4] do not describe the rate at which ondansetron had been administered to the patient. It is not uncommon for residents to administer ondansetron as a bolus perioperatively. Not many clinicians are aware that ondansetron 4 to 8 mg iv should be administered over 2 to 5 min[6] and certainly not as a bolus or in less than 30 s. Perhaps slow administration of ondansetron as recommended over 2-5 min would decrease the incidence of potentially life-threatening adverse effects associated with ondansetron.
  5 in total

1.  Intravenous ondansetron causing severe bradycardia: two cases.

Authors:  Nisha Afonso; Amit Dang; Viraj Namshikar; Sahish Kamat; Padmanabh V Rataboli
Journal:  Ann Card Anaesth       Date:  2009 Jul-Dec

2.  Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report.

Authors:  Nagesha S Kasinath; Osama Malak; John Tetzlaff
Journal:  Can J Anaesth       Date:  2003-03       Impact factor: 5.063

3.  Ondansetron causing near fatal catastrophe in a renal transplant recipient.

Authors:  Sandeep Sahu; Sunaina Tejpal Karna; Anil Agarwal; Sushil Prakash Ambesh; Aneesh Srivastava
Journal:  Indian J Anaesth       Date:  2011-01

4.  Symptomatic sinus bradycardia: A rare adverse effect of intravenous ondansetron.

Authors:  Md Shahnawaz Moazzam; Farah Nasreen; Shahjahan Bano; Syed Hussain Amir
Journal:  Saudi J Anaesth       Date:  2011-01

5.  Ondansetron induced fatal ventricular tachycardia.

Authors:  R Chandrakala; C N Vijayashankara; Kushal K Kumar; N Sarala
Journal:  Indian J Pharmacol       Date:  2008-08       Impact factor: 1.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.